Background
==========

Severe sepsis is a significant contributor to Intensive Care Unit (ICU) admission and reports vary from 12% to 27% of ICU admissions in different countries \[[@B1]\]. Many more patients develop sepsis following ICU admission. EPIC 2 demonstrated that 51% of ICU inpatients were classified as infected on the day of the point prevalence study. In this study 62% of isolates were identified to be Gram negative, which is worrisome given the dearth of in-development antimicrobials with gram negative coverage \[[@B2]\]. Under dosing of antibiotics has enabled the genesis of resistant strains and this is particularly an issue with fluoroquinolones, aminoglycosides and beta lactams \[[@B3],[@B4]\]. Of particular concern is the ability of fluoroquinolones to engender resistance to other classes of antibiotics \[[@B5]\]. Altered drug pharmacokinetics, due to disease, results in variable antimicrobial drug clearance in critically ill patients (antibiotic regimens are often developed on the basis of drug disposition in non-critically ill volunteers) and further complicates the selection of appropriate dosing schedules for these patients. For optimal dosing, it is necessary to consider the kill characteristics of the antibiotic.

Pharmacokinetic-pharmacodynamic (PK-PD) parameters can be used to indicate the potential for bacterial eradication with antimicrobial therapy. Bactericidal activity can be time-dependent or concentration-dependent. Quinolones exhibit concentration-dependent bacterial killing \[[@B6]-[@B10]\]. Consequently bactericidal activity becomes more pronounced as serum drug concentrations increase to approximately 10 times the minimum inhibitory concentration (MIC.). The goal of ciprofloxacin therapy is to maximise the 24-hr AUC/MIC and the peak/MIC ratios \[[@B10]\]. There is general concern about the emergence of resistance as a result of inadequate doses of ciprofloxacin \[[@B9]\]. A C~pmax~/MIC ratio, where C~pmax~is the maximum steady state serum concentration, of \>10 and an AUC~24~/MIC \~\> 100 have been proposed as predictors of therapeutic efficacy \[[@B10]-[@B12]\]. In clinical practice, C~pmax~is equated with the serum peak level. A number of papers have highlighted the requirement for a re-evaluation of currently recommended antimicrobial dosage regimens for critically ill patients \[[@B13],[@B14]\].

Ciprofloxacin disposition is affected by critical illness, particularly by the presence of organ failure and dosage adjustment is advised in patients with renal failure \[[@B15]\]. In patients with severely impaired renal function, a 50% dosage reduction has been recommended \[[@B16]\]. Some data are extrapolated from non-critical patients with renal failure and others from critically ill patients without renal failure. Doses ranging from 200 mg twice daily to 400 mg three times daily have been used for critically ill patients without renal impairment \[[@B17],[@B18]\].

Renal elimination, including both glomerular filtration and tubular secretion accounts for approximately 66% of ciprofloxacin clearance \[[@B19]\]. In healthy volunteers, the hepatic route accounts for approximately 20% of elimination, with transintestinal excretion also playing a possibly significant role. This is thought to represent a notable compensatory pathway preventing drug accumulation in renal failure. In terms of clearance during continuous renal replacement therapy (CRRT), the method of CRRT used has been presented as an important determinant of the effect of CRRT on clearance, with increased drug clearance via CVVHDF compared to continuous veno-venous haemofiltration (CVVH) \[[@B20]\]. Nonetheless, clearance via CVVH of up to 25% has been reported \[[@B21]\]. It has been recommended therefore that dosing during CVVHDF is focussed on attaining clinically adequate drug concentrations, preferably with concurrent therapeutic drug monitoring.

As a result of the reported variability in ciprofloxacin pharmacokinetic parameters during critical illness, differences in patient populations and CRRT conditions in literature reports and the absence of a consensus on dosing regimens, a prospective pharmacokinetic evaluation of ciprofloxacin during CVVHDF therapy was undertaken.

Methods-
========

Patient Demographics and Clinical Characteristics
-------------------------------------------------

This was an open, prospective pharmacokinetic study in a multidisciplinary, intensive care unit in a university teaching hospital. Ethics approval was obtained from the Joint Ethics Committee (St James\'s/AMNCH) (Reference Number 041008/7804). Clinical trial approval was granted by the Irish Medicines Boards (EudraCT Number 2004-002195-42) and the trial was registered with Current Clinical Trials (ISRCTN52722850). Consent (predominantly consent by proxy) was obtained in compliance with Helsinki declaration. Seven critically ill patients, treated concurrently with intravenous ciprofloxacin and CVVHDF therapy, were enrolled in the study. Intravenous ciprofloxacin 400 mg twice daily administered as a one hour infusion was the dosage regimen generally employed, dosing at all times was at the discretion of the physician. A dosage regimen of ciprofloxacin 400 mg once daily was also analysed for three patients, while a dosage regimen of 200 mg twice daily was also assessed in one patient. MIC susceptibility testing for pathogens isolated was not performed. Instead a representative MIC of 0.5 mg/L was employed based on an analysis of local ecology data. It should be noted that CVVHDF patients in this hospital are prescribed on average 14.3 drugs during CVVHDF, 4.7+/-2.66 are anti-infectives.

CVVHDF conditions
-----------------

CVVHDF was performed at prescribed dialysate rates of 1 or 2 L/hr and ultrafiltration rate of 2 L/hr. This reflects the typical CVVHDF prescription of the unit. The blood flow rate was 200 ml/min, achieved using a Gambro blood pump and Hospal AN69HF haemofilter. For patients 6 and 7, CVVHDF was run heparin-free, due to coagulopathy.

Measurement of Ciprofloxacin Concentrations
-------------------------------------------

Timed serum samples were collected during each dosage interval and ultrafiltrate during 7 dosage intervals (1 per patient). Effluent fluid was collected for the entire dosage interval. The volume of each hourly batch was recorded and a 40 ml sample was taken for analysis. Aliquots from each sample were analysed for ciprofloxacin concentration and for creatinine determination. Total ciprofloxacin concentrations in serum and effluent were measured by the HPLC method of Davis et al \[[@B22]\], adapted for both serum and effluent fluid analysis. Quantitation was based on external standard calibration using the ratio of the peak areas of the analyte and the internal standard (β-hydroxypropyl theophylline). Replicate analysis was performed both on control samples and study samples. Ciprofloxacin hydrochloride monohydrate (1g) (gift from Bayer UK) was used to verify the concentration of the commercial infusion solution, Ciproxin^®^. The extraction efficiency was in excess of 80% in the concentration range 0.5-20.0 μg/ml and the between day coefficient of variation \<10%. Precision was less than 5.0 R.S.D.%. The sensitivity of the assay was 0.5 μg/ml.

Analysis of Serum Concentrations of Ciprofloxacin
-------------------------------------------------

Serum concentrations, from an indwelling arterial cannula, were measured immediately before the infusion was started, immediately after the infusion finished and at 2,3,4,6,8 and 12 hours post infusion where the dosage interval was 12 hr. When the prescribed dosage interval was 24 hr samples were also taken at 18 and 24 hrs. Exact sampling times were recorded. Thus C~pmax~was directly measured.

Pharmacokinetic analysis
------------------------

### Calculating half-life and clearance

Non-compartmental pharmacokinetic methods were used. Pharmacokinetic analysis was performed using WinNonlin pharmacokinetic software, version 5.2, (Pharsight Corporation, North Carolina, U.S.A.). The terminal half-life (t~1/2~) was calculated as 0.693/λ~z~, where λ~z~is the first order terminal elimination rate constant. The area under the plasma concentration-time curves (AUC) were calculated using the linear trapezoidal method. AUC for the study period (n = 12 or 24 hours) was used to calculate the AUC extrapolated to infinity (AUC~0-∞~) by the equation AUC~0-t\*~+ C\*/λ~z~. where C\* is the final plasma concentration, at the final sampling time, t\*. The Total Body Clearance (TBC) was calculated as dose/AUC~0-∞~for profile 4a as this was a first dose, and as dose/AUC~0-τ~at steady state, where τ is the dosage interval, for all other profiles except 2c, 4b and 6c, which were not at steady state.

### Estimating clearance for profiles not at steady state

Profiles 2c, 4b and 6c did not result from initial doses, and could not be considered to be at steady state as they directly followed a change in dose or interval. For these profiles, TBC was estimated as dose/AUC~n0-∞~.

AUC ~n0-∞~in these cases was estimated as (AUC~0-∞~-(C\*~(n-1)~/λ~z(n-1)~)), where C\*~(n-1)~was the final observed concentration at the end of the preceding dose interval, and λ~z(n-1)~was the first order terminal elimination rate constant calculated from the preceding dose interval.

### Calculating volume of distribution at steady state (V~dss~)

Because of the severity of illness body weights could not be accurately monitored, consequently parameters were not weight normalised. Volume of distribution at steady state (V~dss~) for an initial dose was calculated as , where t~inf~is the duration of the infusion, and as from profiles at steady state. In cases where the dosing interval was changed from 24 (at steady state) to 12 hours, the first profile following the change was calculated as a 24 hour interval, with sampling ceasing at 12 hours. This was the case for profiles 6b and 7b. V~dss~was not calculated for profiles 2c, 4b and 6c as these were neither an initial dose or at steady state.

### Calculating sieving coefficients

Sieving coefficients (S) for ciprofloxacin and creatinine were calculated from the time-matched concentrations in effluent and in serum for a single dosage interval, whereby S~creatinine~= C~effluent~/C~serum~and S~cipro~= C~effluent~/C~serum~. The clearance of creatinine was calculated from S~creatinine~and the measured flow of effluent (Q) where Cl~creat~= S~creat~x Q.

The fraction cleared by CVVHDF (F~CVVHDF~) was determined from Cl~CVVHDF~/TBC. The PK-PD parameters C~pmax~/MIC and AUC~0-24~/MIC were employed as predictors of the likelihood of clinical and microbiological response.

Results
=======

Patients
--------

Relevant demographic and clinical data relating to the seven patients studied are presented in Table [1](#T1){ref-type="table"}. Patients were severely ill having renal failure, haemodynamic instability and coagulopathy. Six patients were prescribed ciprofloxacin for documented infection *(Pseudomonas aeruginosa, Escherichia coli)*, while one patient with suspected sepsis was prescribed ciprofloxacin empirically. The median APACHE Π score was 27 (range 25-30).

###### 

Demographic and clinical data of patients on continuous veno-venous haemodiafiltration administered ciprofloxacin

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
      Sex   Age   Diagnosis                                                               Infective\                                        APACHE II score(initial/highest)   CVVHDF Duration(days)   ICU Mortality Outcome
                                                                                          pathogen                                                                                                     
  --- ----- ----- ----------------------------------------------------------------------- ------------------------------------------------- ---------------------------------- ----------------------- -----------------------
  1   M     60    Intestinal Obstruction, Hemicolectomy                                   *Escherichia coli*                                26                                 6                       Survived

                                                                                                                                                                                                       

  2   F     77    Neutropaenic sepsis                                                     *Pseudomonas aeruginosa*                          27                                 5                       Died

                                                                                                                                                                                                       

  3   F     68    Intestinal obstruction, post-operative sepsis and acute renal failure   *Pseudomonas aeruginos*a                          28                                 14                      Survived

                                                                                                                                                                                                       

  4   M     47    Acute pancreatitis, sepsis                                              *Escherichia Coli*                                25                                 14                      Survived

                                                                                                                                                                                                       

  5   F     71    ESRD with severe sepsis                                                 Empiric cover                                     27                                 8                       Died

                                                                                                                                                                                                       

  6   M     57    Hepatic cirrhosis with severe sepsis                                    *Pseudomonas Aeruginosa, Enterococcus faecalis*   29                                 7                       Survived

                                                                                                                                                                                                       

  7   M     28    Acute liver failure with severe sepsis                                  *Pseudomonas aeruginosa*                          30                                 11                      Survived
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CVVHDF conditions
-----------------

The actual flow rates achieved were recorded and compared with the target flow rates. The mean effluent flow rate achieved was 3.35 +/- 0.50 L/hr (Range: 2.9 - 4.0 L/hr). The mean duration of CVVHDF therapy was 9.3 +/- 3.7 days. The mean number of filters used per dosage interval was 1.1. The mean duration of use of a filter was 50.6 hours.

Pharmacokinetic profiles
------------------------

Seventeen pharmacokinetic profiles were obtained from these seven patients. The ciprofloxacin pharmacokinetic parameters estimated from each patient\'s pharmacokinetic profile, during treatment with CVVHDF are presented in Table [2](#T2){ref-type="table"}. Ciprofloxacin t~1/2~during CVVHDF was variable, ranging from 5.15 to 39.4 hours, with a median of 13.8 hours, reflecting a median elimination rate constant of 0.050 (range 0.018-0.135) hr^-1^. The average t~1/2~of patients 1 and 4 (both had hepatic impairment) were 37.3 and 25.9 hours, respectively. These t~1/2~values are seven to eight times that obtained in patients with normal renal function, and were the highest obtained in the current study. Patient 4 had evidence of liver injury that may have resulted in impaired biliary clearance, and patient 1 had concurrent alcoholic liver disease, which may have contributed to the prolonged t~1/2~. In patient 4, profile 4a, the clearance was calculated using the estimated AUC~0-∞~, as this profile was measured following the initial dose. The long half life calculated (25 h) in combination with the lower volume of distribution lead to a comparatively low estimated TBC. The t~1/2~observed in patients 3 and 5, 6.73 and 7.00 respectively, were closer to those seen in patients with normal renal function. The median TBC of ciprofloxacin was 9.90 (range 3.10-13.2) L/hr (\~0.14 L/hr/kg based on a 70 kg patient). This value represents hepatic, residual renal and transintestinal ciprofloxacin clearance, in addition to ciprofloxacin clearance by the filter. The V~dss~for ciprofloxacin during CVVHDF therapy ranged from 79.5-555 L with a median of V~dss~of 125 L. The mean C~pmax~concentration following administration of 400 mg every 12 hours was 5.8 +/- 1.0 mg/L.

###### 

Estimates of pharmacokinetic parameters obtained from multiple ciprofloxacin serum concentrations in a dosage interval using non-compartmental methods

  --------------------------------------------------------------------------------------------------------
  Patient\   Dose\   Dosage\     T~1/2~(hrs)   k\          AUC~0-τ~\*\        TBC (Dose/AUC)\   Vd~ss~\
  Profile    (mg)    Interval\                 (hr^-1^)    ~(τ\ =\ dosage~\   (L/hr)            (L)
                     (hours)                               ~interval)~\                         
                                                           (mg.hr/L)                            
  ---------- ------- ----------- ------------- ----------- ------------------ ----------------- ----------
  1.A        400     12          35.2          0.020       35.4               11.3              524

  1.B        400     12          39.4          0.018       38.3               10.4              555

  **Mean**                       **37.3**      **0.019**   **36.8**           **10.9**          **539**

                                                                                                

  2.A        200     12          5.15          0.135       15.2               13.2              104

  2.B        200     12          13.8          0.050       16.5               12.2              215

  2.C        400     12          12.4          0.056       51.8               7.72              

  **Mean**                       **10.5**      **0.080**                      **11.0**          **160**

                                                                                                

  3.A        400     12          5.97          0.116       38.9               10.3              79.5

  3.B        400     12          7.50          0.092       40.2               10.0              97.3

  **Mean**                       **6.73**      **0.104**   **39.5**           **10.1**          **88.4**

                                                                                                

  4.A        400     24          24.7          0.028       129                3.10              111

  4.B        400     12          27.2          0.026       81.5               4.91              

  **Mean**                       **25.9**      **0.027**                      **4.00**          

                                                                                                

  5.A        400     12          8.44          0.082       40.4               9.90              107

  5.B        400     12          5.77          0.120       37.8               10.6              81.1

  5.C        400     12          6.80          0.102       40.9               9.78              88.2

  **Mean**                       **7.00**      **0.101**   **39.7**           **10.1**          **92.2**

                                                                                                

  6.A        400     24          14.0          0.050       43.4               9.22              175

  6.B        400     12          14.7          0.047       54.0               7.40              151

  6.C        400     12          16.5          0.042       49.6               8.06              

  **Mean**                       **15.0**      **0.046**                      **8.23**          **163**

                                                                                                

  7.A        400     24          15.1          0.046       50.6               7.91              164

  7.B        400     12          10.4          0.067       39.4               10.1              139

  **Mean**                       **12.7**      **0.056**                      **9.00**          **151**
  --------------------------------------------------------------------------------------------------------

\* τ taken to be 24 hours for first profile immediately following a change in prescribed dosage interval (profiles 6b and 7b)

The clearances of ciprofloxacin and creatinine by CVVHDF are presented in Table [3](#T3){ref-type="table"}. The mean clearance of ciprofloxacin by CVVHDF was 2.47 +/- 0.29 L/hr, thus the clearance of ciprofloxacin by CVVHDF was on average 26% of the TBC, reflected in the mean F~CVVHDF~of 0.26 (Table [3](#T3){ref-type="table"}). This value excludes that of patient 4. In this case a significant fraction (0.74) of the clearance is calculated to have occurred via CVVHDF, and was therefore considered an atypical value.

###### 

Ciprofloxacin and Creatinine Clearance by continuous veno-venous haemodiafiltration.

  -------------------------------------------------------------------------------------------------------------------
  Patient           Cl~CVVHDF~\         Cl~CREAT~\          F~CVVHDF~           Measured effluent\   Total Body\
                    (L/hr)              (L/hr)                                  fluid rate\          Clearance\
                                                                                (L/hr)               (L/hr)
  ----------------- ------------------- ------------------- ------------------- -------------------- ----------------
  1 A               2.8                 2.9                 0.25                4.0                  11.3

  2 C               2.4                 2.6                 0.31                3.4                  7.72

  3 B               2.7                 2.9                 0.27                3.9                  9.96

  4 A               2.3                 2.3                 0.74                2.9                  3.10

  5 A               2.2                 2.6                 0.22                3.0                  9.90

  6 C               2.1                 2.4                 0.26                2.9                  8.06

  7 B               2.8                 2.9                 0.28                4.0                  10.1

                                                                                                     

  **Mean +/- SD**   **2.47 +/- 0.29**   **2.66 +/- 0.25**   **0.26 ± 0.03\***   **3.35 +/- 0.50**    **8.60 ± 2.7**
  -------------------------------------------------------------------------------------------------------------------

\* Excluding value from patient 4A

The S~cipro~was 0.70 +/- 0.06. A simple method for estimating drug clearance through the filter, without measuring drug levels, involves using the non-protein bound fraction (f~u~) of ciprofloxacin as an estimate of the sieving coefficient, as it is the unbound fraction that crosses the filter. Hoffken et al \[[@B23]\] and Joos et al \[[@B24]\] have reported f~u~values for ciprofloxacin of 0.6 and 0.78 respectively. Applying these values to the observed flow rates in this study gives clearance estimates of 2.0 L/hr and 2.7 L/hr, which approximate the measured value of 2.47 L/hr. The sieving coefficient for creatinine (0.82 +/- 0.04) was quite similar to that estimated for ciprofloxacin. A correlation between ciprofloxacin clearance due to CVVHDF (y) and creatinine clearance by the filter (x) was observed (y = -0.29 + 1.03x, r^2^= 0.76) and is illustrated in Figure [1](#F1){ref-type="fig"}. Ciprofloxacin and creatinine clearances over time were examined in order to identify any change in filter efficiency over time. There was little variation in filter performance as the clearance of both creatinine and ciprofloxacin remaining relatively constant.

![**Relationship between ciprofloxacin clearance via CVVHDF (L hr^-1^) and creatinine clearance (L hr^-1^)**.](1472-6904-11-11-1){#F1}

Within the observed range of effluent flow rates and CVVHDF ciprofloxacin clearance rates in the current study, there is a suggested trend (r^2^= 0.94) of increasing ciprofloxacin clearance with higher effluent fluid flow rates, which is illustrated in Figure [2](#F2){ref-type="fig"}.

![**Relationship between ciprofloxacin clearance by CVVHDF (L hr^-1^) and effluent flow rate (L hr^-1^)**.](1472-6904-11-11-2){#F2}

Pharmacokinetic - Pharmacodynamic parameters
--------------------------------------------

The PK-PD parameters, C~pmax~/MIC ratios and the ratio of AUC~0-24~/MIC, achieved with a ciprofloxacin dosing regimen of 400 mg ciprofloxacin every 12 hours are summarised in Table [4](#T4){ref-type="table"}.

###### 

Cpmax/MIC ratios for representative MICs for patients treated with 400 mg ciprofloxacin every 12 hours during critical illness and continuous veno-venous haemodiafiltration therapy.

  ----------------------------------------------------
  Patient\   Cpmax/MIC ratio\   AUC~0-24~/MIC ratio\
  ID         (MIC = O.5 mg/L)   (MIC = O.5 mg/L)
  ---------- ------------------ ----------------------
  1          10.3               147

  2          10.2               207

  3          12.8               158

  5          14.6               159

  6          10.0               199
  ----------------------------------------------------

The median AUC~0-24~/MIC ratio for patients administered Ciprofloxacin 400 mg twice daily was 161. An AUC~0-24~/MIC\~ \> 100 has been propounded as an indicator of adequate ciprofloxacin dosing \[[@B12]\].

Discussion
==========

The pharmacokinetic parameter estimates obtained, half life \[median 13.8 (range 5.15-39.4) hours\], TBC \[median 9.90 (range 3.10-13.2) L/hr\] and median V~dss~of 125 (range 79.5-555) L illustrate the high level of inter-patient variability in ciprofloxacin disposition in critically ill patients during CVVHDF. The t~1/2~of ciprofloxacin, approximately 4 hours in patients with normal renal function, doubles in patients with severe renal impairment. In general, accumulation will not be observed with 12 hour dosing as this interval is greater than the half-life, in patients without liver dysfunction. As significant accumulation was observed with an interval of eight hours in previous studies \[[@B15],[@B17],[@B25]\] a longer dosage interval of 12 hours for patients on CVVHDF should therefore be considered. Patients 1,4,6 and 7 had average half-lives varying from 13-15 hours (patients 6 and 7) to greater than 25 hours (patients 1 and 4), demonstrating the variability of pharmacokinetic profiles in this patient group, and also likely reflecting decreased hepatic clearance in these four patients.

Wallis et al \[[@B15]\] reported a similarly reduced ciprofloxacin clearance in six patients with renal failure, treated with 200 mg ciprofloxacin three times daily during CVVHDF therapy (0.06-0.25 L/hr/kg).

The median volume of distribution of 125 L (mean 185 +/- 155) is similar to values reported by Wallis et al \[[@B15]\] (mean: 135+/- 27 L) estimated from six patients treated with 200 mg every 8 hours and by Lipman et al \[[@B18]\] (range: 0.77 - 2.52 L/kg) for critically ill patients. The current patient sample showed greater variability: Patient 1, in particular, had a very high V~dss~of 539L. The average V~dss~for the other 6 patients was 126+/-43L. These values compare well with those detailed above from Wallis et al \[[@B15]\], and probably reflect more typical V~dss~values of ciprofloxacin in this patient population. However, the high V~dss~calculated from patient 1 serves as evidence of the unpredictable drug disposition which can occur in critically ill patients, reflecting greater degrees of capillary leak in keeping with the severity of illness.

A practical and useful finding was that, within the range studied, creatinine clearance may serve as a clinical surrogate for ciprofloxacin clearance on CVVHDF. This relationship is clinically important as ciprofloxacin is not routinely assayed in most hospitals. The relationship did not decline over the life of the filter. This relationship may serve as a useful guide to dosing ciprofloxacin within this range of creatinine clearance values.

As effluent flow rates increased, there was a suggested trend of increased ciprofloxacin clearance via CVVHDF. However, there was no observed change in TBC with increasing effluent flow rate. This illustrates the varying role of compensatory and alternative elimination methods such as hepatic elimination. Further studies on this association between effluent flow rate and ciprofloxacin clearance via CVVHDF to investigate the presence of a cause-effect relationship would be beneficial and may helpfully influence dosing decisions. This is of importance in particular as increased effluent flow rates may be used for purposes other than enhancing drug clearance, and therefore TBC in such patients can be difficult to estimate in the absence of plasma concentration data and due to the varying influence of alternative elimination routes. Further insight into the effect of increasing effluent flow rate on clearance via CVVHDF is therefore desirable. Prospectively, such dosing considerations are often hampered by the discrepancy between prescribed and achieved flow rates.

CVVHDF was responsible for clearing approximately one quarter of all ciprofloxacin eliminated. Its relative contribution to ciprofloxacin TBC will be greatest in patients with concurrent hepatic and renal dysfunction, as in these patients, CVVHDF will become a proportionately more significant route. Therefore care is required in dosing patients with concurrent renal and hepatic failure/impairment to avoid accumulation of ciprofloxacin. Interestingly, clearance of ciprofloxacin via CVVH of up to 25% has been reported \[[@B21]\], which is similar to that observed in the current study using CVVHDF. This implies that both dialysis parameters and patient specific parameters have a role to play in the observed variability in clearance via CRRT, in addition to the CRRT method used.

There is now significant evidence that correct and timely antibiotic choices will save more lives than virtually all other ICU therapies \[[@B4],[@B26]\]. A C~pmax~/MIC ratio of \~\>10 has been suggested \[[@B9],[@B11]\] as desirable and thus a 400 mg twice daily regimen appears to achieve these target concentrations during CVVHDF therapy (Table [4](#T4){ref-type="table"}), 200 mg twice daily being inadequate. For ciprofloxacin 400 mg twice daily, the median C~pmax~achieved in this study was 5.2 (range 5.0-7.3) mg/L (mean 5.8 ± 1.0 mg/L), which represented a median C~pmax~/MIC ratio (based on an MIC of 0.5 mg/L) of 10.3. The median AUC~0-24~was 80.4 (range 70.8-104) mg.hr/L (mean 83.0 ± 11.1 mg.hr/L), which corresponds to a median AUC~0-24~/MIC ratio of 161 (range 142-207). A suggested characteristic of adequate dosing for ciprofloxacin is an AUC~0-24~/MIC ratio \> 100.

Wallis et al \[[@B15]\] reported lower C~pmax~concentrations and AUC~0-24~values with a lower daily dose of 600 mg ciprofloxacin, compared to the 800 mg daily dose used in this study. The CVVHDF conditions in our study were similar to those reported by Wallis et al \[[@B15]\]. Wallis et al \[[@B15]\] used a dosing schedule of 200 mg every 8 hours and the mean C~pmax~concentration was 3.5 +/- 0.5 mg/L. This dosing schedule achieves on average a C~pmax~/MIC ratio of 7 (based on a MIC of 0.5 mg/L). The mean AUC~0-24~achieved by the same dosing schedule of 200 mg every 8 hours was 48.3 +/- 8.7 mg.h/L, equivalent to a AUC~0-24~/MIC ratio of 96.6 +/- 17.4, on the basis of a MIC value of 0.5 mg/L. Malone et al \[[@B27]\] reported a mean C~pmax~of 3.9 mg/L (C~pmax~/MIC ratio; 7.8) for three patients treated with 400 mg ciprofloxacin every 24 hours during CVVHDF therapy. The mean AUC~0-24~with this dosing schedule was 56.8 mg.h/L, which represents an AUC~0-24~/MIC ratio of 114 (assuming an MIC of 0.5 mg/L). The CVVHDF conditions employed by Malone et al \[[@B27]\] were different from those used in the current work.

On the basis of these pharmacodynamic considerations, the dosing schedule utilised in this study gives better cover than previously studied dosage strategies and should serve as a pharmacokinetically and pharmacodynamically valid dose guide in the appropriate clinical circumstances.

One limitation of this work is common to all carried out in this field, that patient numbers are small, and as such the conclusions that can be drawn are limited to a very narrow patient cohort. A consideration for future research might be that a randomised crossover design could be employed to add further clarity to dosing recommendations. As both antimicrobial doses, and dialysis parameters such as flow rate, are frequently adjusted on the basis of changing clinical need in the intensive care setting, there are ethical difficulties surrounding the set up and design of such trials.

Another limitation was that liver dysfunction or impairment was not characterised in a standardised manner. However this is difficult in these patients due to blood product and vitamin K administration, particularly in septic and coagulopathic patients and also because of concurrent hepatotoxic drug administration. Similarly, the varying nature from day to day of hepatic/renal function in many critically ill patients suggest that calculations based on steady state be interpreted with caution, as clearance is likely to be variable. Furthermore, it is extremely difficult to quantify any residual renal function, and thereby contribution to the clearance, that these patients made have had.

Conclusion
==========

Our results suggest that a dose rate of 400 mg every 12 hours, will achieve the recommended PK-PD goals in *most*patients on CVVHDF. Twice daily dosing of ciprofloxacin maximised peak concentrations, while minimizing accumulation. Concomitant hepatic and renal dysfunction results in a prolonged elimination half-life. Creatinine clearance by the filter may be used to estimate ciprofloxacin clearance by CVVHDF (within the range studied). Thus in the absence of ciprofloxacin plasma levels, creatinine clearance by the filter could be considered as a surrogate marker for ciprofloxacin clearance in patients, this may be particularly useful when other routes of elimination are impaired.

The data suggest that drug clearance increases with increasing effluent flow rate, which in turn may require even higher ciprofloxacin dosing. This association between effluent flow rate and drug clearance requires further elucidation to determine the nature of any cause-effect relationship.

While a 400 mg dose administered at 12 hourly intervals achieved adequate C~pmax~concentrations and lower doses may result in target serum concentrations in some patients with hepatic dysfunction, given the general emergence of ciprofloxacin resistance and the wide therapeutic index of ciprofloxacin, it may be advisable to maintain the higher ciprofloxacin dose as the mainstay of therapy. The possibility of accumulation in patients where more than one elimination route is impaired should be considered and this can be addressed by extension of the dosage interval.

Key Messages
============

• Ciprofloxacin 400 mg twice daily IV will achieve the recommended PK-PD goal (AUC~0-24~/MIC ratio \>125) in most patients on CVVHDF.

• Concomitant hepatic and renal impairment results in a prolonged ciprofloxacin elimination half life, therefore dosage interval extension may be required.

• Creatinine clearance by the filter correlates well with ciprofloxacin clearance by the filter, therefore creatinine clearance by the filter (in the range studied) may be used as a surrogate for ciprofloxacin clearance.
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